28 February 2008 Antitope Ltd (Cambridge, UK), a leader in the generation of therapeutic humanized antibodies, and Keel Pharmaceuticals, Inc. (Cambridge, MA), an emerging leader in the development of therapeutics ...

  Antitope to Present at 2nd Annual Conference on Recombinant Antibodies Melia Hotel, Berlin, Feb 27th 2008 Dr Matthew Baker, Chief Scientific Officer, will be presenting a paper entitled ...

Dr Frank Carr, Director of Biologics Research will be presenting a paper entitled Overcoming Adverse Immunogenicity Against Therapeutic Antibodies .  This paper will discuss the process of engineering antibodies ...

23rd January 2008 - Antitope Ltd., a privately-held antibody and protein engineering company, today announced a research agreement with the China Synthetic Rubber Corporation (CSRC). Under the Agreement, Antitope will ...

  12th December 2007 -Antitope Ltd. today announced a research collaboration with UCB Celltech ( UCB ) where Antitope will apply EpiScreenTM technology to profile the immunogenicity of therapeutic monoclonal ...

19 November 2007, Cambridge (UK) -  Antitope Ltd., today announced they have entered into a research collaboration with Centocor Inc..  The research collaboration will employ Antitope's EpiScreenTM technology to assist ...

18th September 2007 - Antitope Ltd., a leader in antibody and protein engineering, today announced a research agreement with Fraunhofer Institute for Cell Therapy and Immunology (Fraunhofer IZI). Under the ...

July 30th, 2007 - Cambridge / Jerusalem - Antitope Ltd., inventors of the Composite Human AntibodyTM technology, announced a research and product development agreement with ProtAb Ltd. (a wholly-owned portfolio ...

24th April 2007 Antitope Ltd., announced a research agreement with the Cambridge Antibody Technology (CAT) for the generation of novel biologics for the potential treatment of cancer.  As part of ...

   23th April 2007 - Antitope Ltd. today announced a research agreement with Medtronic Inc. for the generation of a novel biologic.  As part of the agreement, Antitope will apply ...

Antitope will be participating in the Business Partnering Forum at the BIO International Convention and welcome the opportunity to discuss potential collaborations with companies that are interested in assessing and/or ...

 Dr Frank Carr, Director of Biologics Research will be presenting a paper entitled Therapeutic Antibodies Without Helper T cell Epitopes .  This paper will discuss the process and benefits ...

 Dr Frank Carr, Director of Biologics Research will be presenting a paper entitled Immunogenicity and Antibody Therapeutics

23rd February 2007 - Antitope Ltd., announced a research agreement with the Dana Farber Cancer Institute, Inc. ( Dana-Farber ) for the generation of novel biologics for the potential treatment ...

Antitope to present at Strategies and Techniques for Immunogenicity Testing at San Diego, March 8-9th 2007. Dr Matthew Baker, Chief Scientific Officer, will be presenting a paper entitled ...

Antitope Limited, UK. Announces Antibody Research Agreement with ARIUS Research, Inc. - 10th January 2007. Antitope Ltd., a leader in the development of Composite Human Antibody technology for the generation ...

Antitope Limited, UK. Announces Research Agreement With GlaxoSmithKline plc - 2nd January 2007 - Antitope Ltd., a leading company with technologies for the assessment and removal of immunogenicity in therapeutic ...